Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF

AIDS Patient Care and STDs

Volumn 24, Issue 2, 2010, Pages 87-96

  Hodder, Sally L ^a   Mounzer, Karam ^b,c   Dejesus, Edwin ^d   Ebrahimi, Ramin ^e   Grimm, Kristy ^f   Esker, Stephen ^f   Ecker, Janet ^e   Farajallah, Awny ^f   Flaherty, John F ^e  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b Philadelphia Fight   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ORLANDO IMMUNOLOGY CENTER   (United States)

^e GILEAD SCIENCES   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; TENOFOVIR; VIRUS RNA;

ADULT; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL INSTABILITY; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERSONALITY DISORDER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SLEEP DISORDER; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADENINE; ADOLESCENT; ANTI-HIV AGENTS; BENZOXAZINES; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PATIENT COMPLIANCE; PATIENT PREFERENCE; PHOSPHONIC ACIDS; PUERTO RICO; QUALITY OF LIFE; REVERSE TRANSCRIPTASE INHIBITORS; SEVERITY OF ILLNESS INDEX; TABLETS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 77149125963     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2009.0259     Document Type: Article

References (23)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services, December 1, 2009; 1-161. Available at http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (Accessed December 31, 2009).
2. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatmentnaive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008;47:74-78.
3. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-260.
4. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologie changes - A 96-week analysis. J Acquir Immune Defic Syndr 2006; 43:535-540.
5. Mathias AA, Hinkle J, Menning M, Hui J, Kaul S, Kearney BP. Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. J Acquir Immune Defic Syndr 2007;46:167-173.
6. Molina JM, Journot V, Morand-Joubert L, et al. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: A randomized trial. J Infect Dis 2005;191:830-839.
7. Campo RE, Cohen C, Grimm K, Shangguan T, Maa J, Seekins D. Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction, and adherence with low rates of virological failure in virologically suppressed patients. Int J STD AIDS (in press).
8. Cooper VL, Home R, Moyle G, Fisher M. Simplification with easier emtricitabine and tenofovir (SWEET): Results of a 48 week analysis of patients' perceptions of treatment and adherence [Abstract TUPE0065]. Presented at XVII International AIDS Conference. Mexico City, Mexico: August 3-8, 2008.
9. DeJesus E, Ruane P, McDonald C, et al. Impact of switching virologically suppressed, HTV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clin Trials 2008;9:103-114.
10. DeJesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single tablet regimen consisting of efavirenz, emtricitabine, and tenofovir DF versus unmodified antiretroviral therapy in virologically suppressed, HIV-linfected patients. J Acquire Immune Defic Syndr 2009;51:163-174.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
12. Ware JE, Snow KK, Kosisnki M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, 1993.
13. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials 2004;5:74-79.
14. Walsh JC, Mandalia S, Gazzard BG Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002;16:269-277.
15. Wolf J, Janssen F, Lublin H, et al. A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-ETA). Curr Med Res Opin 2007;23:2313-2323.
16. Taylor D, Hanssens L, Loze JY, Pans M, L'Italien G, Marcus RN. Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study. Eur Psychiatry 2008;23:336-343.
17. Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol 2001;54(Suppl 1):S77-S90.
18. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-1310.
19. Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials 2008;9:164-176.
20. Molina JM, Podsadecki TJ, Johnson MA, et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses 2007;23:1505-1514.
21. Stone VE, Jordan J, Toison J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: Self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004;36:808-816.
22. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: A metaanalysis. Clin Infect Dis 2009;48:484-488.
23. Sustiva [package insert], Princeton, NJ: Bristol-Myers Squibb; 2009.